Cytosorbents基本情况

browser_result

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.

CytoSorbents At a Glance (NASDAQ: CTSO) • Partnered with leading multi-national corporations: • Now seeking U.S. FDA and Health Canada approval for DrugSorb-ATR, an equivalent polymer technology to CytoSorb, to reduce perioperative bleeding during cardiac surgery by removing a

CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own or have bought CTSO stock by the close of trading on Friday, December 13, 2024 will be considered stockholders of record on December 16, 2024.

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

CytoSorbents : Investor Presentation December 2024

Cytosorbents (NASDAQ:CTSO) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.